FTC Takes Action Against Pharmacy Benefit Managers
Recently, the Federal Trade Commission (FTC) took a notable step to address the rising costs of insulin by filing a formal complaint against three major pharmacy benefit managers (PBMs): CVS Health Inc’s Caremark, Cigna Corp’s Express Scripts, and UnitedHealth Group Inc’s Optum. The FTC alleges that these companies have engaged in unfair and anti-competitive practices, resulting in inflated prices for essential insulin medications.
Claims of Unfair Practices
The FTC's complaint points out that these PBMs have developed a financial model that primarily benefits them, focusing on drug rebates that often result in increased costs for patients. This is especially concerning, since these PBMs manage around 80% of prescriptions in the United States, which gives them significant influence over drug pricing.
Effect on Patients
The tactics used by the major PBMs impact patients significantly, particularly those who are most vulnerable. Many patients find themselves facing higher out-of-pocket expenses for vital diabetes medications, as PBMs often prefer higher-priced drugs to capitalize on profitable rebate deals with manufacturers.
Examining Inflated Insulin Prices
The FTC argues that the high cost of insulin is a direct outcome of the rebate-driven model employed by these PBMs. This model not only aims for profit but also tends to leave out lower-cost insulin options from their formularies, forcing many patients to spend more and worsening the financial burden for those managing diabetes.
Historical Price Comparisons
Take Eli Lilly And Co’s Humalog as an example; its list price skyrocketed from $21 in 1999 to $274 in 2017. Despite the availability of cheaper alternatives, the higher rebates have led PBMs to recommend the more expensive options, putting more financial pressure on patients who rely on these medications.
Investigation of Drug Manufacturers
The FTC isn't just examining PBMs; it's also scrutinizing the role of drug manufacturers, such as Eli Lilly, Novo Nordisk A/S, and Sanofi SA, for their contribution to insulin pricing. As the investigation continues, additional actions may be taken against these companies.
Effects on Patients
The rebate-centric pricing model has allowed the Big Three PBMs to maintain significant revenues from rebates and fees, ultimately harming patient care. Patients with high deductibles or those facing coinsurance particularly suffer, often dealing with costs that surpass what insurers pay overall for these crucial medications.
Market Reactions to the Complaint
In light of the FTC's complaint, there were minor fluctuations in the stock prices of the involved companies. CVS Health's stock fell by 1.61% to $57.49, while UnitedHealth Group's stock decreased by 0.29%, ending at $575.39. Interestingly, Cigna Corp’s stock experienced a slight increase of 0.07%, reaching $357.52.
Frequently Asked Questions
What is the FTC's complaint about?
The FTC is accusing major pharmacy benefit managers of engaging in practices that inflate insulin prices, thereby affecting patient access to essential medications.
How do PBMs affect medication prices?
Pharmacy benefit managers impact medication pricing by controlling the drugs included in insurance formularies and favoring rebates, which often leads to higher out-of-pocket costs for patients.
Which drug manufacturers are under scrutiny?
The FTC is looking into several manufacturers, including Eli Lilly, Novo Nordisk, and Sanofi, regarding their influence on insulin pricing strategies.
What are the consequences for patients?
Patients, especially those with high deductibles, are experiencing elevated out-of-pocket costs for insulin due to the rebate-driven pricing structure.
How has the stock market reacted?
After the FTC's complaint, stocks for CVS Health and UnitedHealth Group dropped slightly, while Cigna Corp’s stock saw a modest rise.
